OSE ImmunotherapeuticsORPOF 41 3-Year RORE % is 39.54 as of Dec. 2025. GuruFocus rates ORPOF with a GF Score™ of 41/100 and a GF Value™ of $3.35 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,294 Biotechnology companies, OSE Immunotherapeutics ranks better than 86.48% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
OSE Immunotherapeutics's 3-Year RORE % for the quarter that ended in Dec. 2025 was 39.54%.
The industry rank for OSE Immunotherapeutics's 3-Year RORE % or its related term are showing as below:
ORPOF's 3-Year RORE % is ranked better than 86.48% of 1294
companies
in the Biotechnology industry
Industry Median: -11.54
vs ORPOF: 39.54
OSE Immunotherapeutics (OTCPK:ORPOF) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
OSE Immunotherapeutics 3-Year RORE % Related Terms
OSE Immunotherapeutics 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ORPOF vs VRTX, REGN, ALNY: 3-Year RORE % Comparison
For the Biotechnology subindustry, OSE Immunotherapeutics's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OSE Immunotherapeutics 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OSE Immunotherapeutics's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where OSE Immunotherapeutics's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
OSE Immunotherapeutics (ORPOF) has a 3-Year RORE % of 39.54 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on OSE Immunotherapeutics and its competitors. According to the industry distribution chart, OSE Immunotherapeutics ranks #175 out of 1294 companies in the Biotechnology industry, placing it in the top 13.5%.
Is OSE Immunotherapeutics' 3-Year RORE % too high?
OSE Immunotherapeutics' current 3-Year RORE % is 39.54. Based on the distribution chart, OSE Immunotherapeutics ranks #175 out of 1294 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, OSE Immunotherapeutics has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OSE Immunotherapeutics' 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OSE Immunotherapeutics ranks #175 out of 1294 companies for 3-Year RORE %. This places OSE Immunotherapeutics in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on OSE Immunotherapeutics and its competitors. OSE Immunotherapeutics's current 3-Year RORE % is 39.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OSE Immunotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, OSE Immunotherapeutics (ORPOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.35, compared to a current price of $4.43 — trading 32.2% above its estimated fair value. The current 3-Year RORE % is 39.54. OSE Immunotherapeutics' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For OSE Immunotherapeutics (ORPOF), the current 3-Year RORE % is 39.54 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OSE Immunotherapeutics (ORPOF) Overvalued in 2026?
Based on GuruFocus' analysis, OSE Immunotherapeutics stock appears to be overvalued.
The current stock price of $4.43 is trading 32.2% above its estimated GF Value™ of $3.35.
GuruFocus considers OSE Immunotherapeutics to be Significantly Overvalued.
Key valuation signals for ORPOF:
3-Year RORE %: 39.54
GF Value™: $3.35 vs. price of $4.43 (32.2% above fair value)
No single metric tells the full story. See the ORPOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
41GF Score
Get the complete analysis for ORPOF
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORPOF has been successfully added to your 
